Pharming Technologies B.V. controls over 90 percent of the total number of shares and votes in Abliva
On 20 February 2025, Pharming Technologies B.V. announced that the company controls in total 1,494,181,625 shares and votes in Abliva, corresponding to approximately 92.7 percent of the total number of shares and votes in Abliva.
On March 6, 2025, the offer was closed with Pharming controlling 97.47 percent of the shares in Abliva. Abliva has been delisted from Nasdaq Stockholm, and the last day of trading in the Abliva share on Nasdaq Stockholm was on March 17, 2025.
The acceptance period for the Offer commenced on 16 January 2025. On 7 February 2025, Pharming Technologies B.V. announced that the company controlled in total 1,413,841,472 shares and votes in Abliva, corresponding to approximately 87.7 percent of the total number of shares and votes in Abliva, and that the Offer had been declared unconditional.
For further information from Pharming Technologies B.V. about the Offer, see: http://www.raredisease-offer.com/
Statement by the Board of Directors of Abliva AB regarding the public cash offer from Pharming Technologies B.V.
The Board of Directors of Abliva AB unanimously recommends that the shareholders of Abliva AB accept the public cash offer from Pharming Technologies B.V.
This statement is made by the Board of Directors of Abliva AB pursuant to section II.19 of the Nasdaq Stockholm takeover rules (“Section II.19”), (the “Takeover Rules”).
Pharming Technologies B.V. announced on December 15, 2024, a public cash offer to acquire all shares in Abliva AB (the “Shares”) for SEK 0.45 per Share (the “Offer”).
Abliva’s three largest sharholders, holding in aggregate approximately 49.82 percent of the total number of shares and votes in Abliva, have undertaken to accept the Offer, subject to certain conditions.
According to what Pharming Technologies B.V. has stated in its press release announcing the Offer, the plans for the future business and general strategy of Abliva do not currently include any material changes. There are currently no decisions on any changes that may impact Abliva’s employees and management, including their terms of employment, Abliva’s organization or operational sites.